Echeverría et al. previously demonstrated that the PPAR-α pathway can upregulate nuclear factor erythroid 2-related factor-2 (Nrf2) to increase the cellular antioxidant potential and downregulate nuclear factor of κ-light chain of enhancer-activated B cells (NF-κB) in nonalcoholic fatty liver disease (NAFLD) [14]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.